Published in Law and Health Weekly, May 19th, 2007
"We're off to a strong start in 2007," said Robert C. Strauss, Noven's President, CEO & Chairman. "Sales of our Vivelle-Dot(R) and Daytrana(TM) products contributed to a 90% increase in first quarter revenues. This increase in revenues, together with a significant improvement in our overall gross margin, contributed to a near ten-fold increase in net income. Additionally, we received during the quarter the first of three potential $25 million milestones related...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.